BamSEC and AlphaSense Join Forces
Learn More

Karyopharm Therapeutics Inc. – Material Contracts

NASDAQ: KPTI    
Share price (11/6/26): $0.05    
Market cap (11/6/26): $1.245 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 86 pages Restructuring Support Agreement
12/34/56
EX-10.2
from 8-K 21 pages September 10, 2026 Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 Newton, Ma 02459 Attention: Chief Financial Officer Re: Fee Agreement Pursuant to Forbearance Agreement Ladies and Gentlemen
12/34/56
EX-10.1
from 8-K 55 pages Forbearance Agreement and Limited Waiver to Indentures
12/34/56
EX-10.6
from 10-Q 4 pages Karyopharm Therapeutics Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.5
from 10-Q 5 pages Karyopharm Therapeutics Inc. Restricted Stock Unit Agreement (Non-Employee Director) 2022 Equity Incentive Plan Notice of Grant
12/34/56
EX-10.4
from 10-Q 11 pages Karyopharm Therapeutics Inc. Restricted Stock Unit Agreement (Performance Vested) 2022 Equity Incentive Plan Notice of Grant
12/34/56
EX-10.3
from 10-Q 10 pages Karyopharm Therapeutics Inc. Restricted Stock Unit Agreement (Performance Vested) 2022 Equity Incentive Plan Notice of Grant
12/34/56
EX-10.2
from 10-Q 2 pages Amendment No. 5 to 2022 Equity Incentive Plan of Karyopharm Therapeutics Inc. * * *
12/34/56
EX-10.3
from 10-Q 23 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 41 pages Securities Purchase Agreement
12/34/56
EX-10.37
from 10-K 5 pages October 8, 2025 Delivered by Email
12/34/56
EX-10.35
from 10-K 5 pages October 7, 2025 Delivered by Email Richard Paulson Dear Richard
12/34/56
EX-10.32
from 10-K 5 pages October 7, 2025 Delivered by Email Sohanya Cheng Dear Sohanya
12/34/56
EX-10.28
from 10-K 5 pages October 7, 2025 Delivered by Email Lori Macomber Dear Lori
12/34/56
EX-10.25
from 10-K 8 pages Karyopharm Therapeutics Inc. Annual Bonus Plan Most Recently Approved by the Board of Directors on December 12, 2025
12/34/56
EX-10.12
from 10-Q 3 pages Amendment No. 4 to License Agreement by and Between Karyopharm Therapeutics Inc. and Berlin-Chemie AG
12/34/56
EX-10.11
from 10-Q 7 pages Fourth Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.10
from 10-Q 7 pages Third Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.9
from 8-K 27 pages Registration Rights Agreement
12/34/56